GILD Gilead Total Asset Value of Company

GILD (Gilead Sciences Inc) - company brandmark

Gilead Sciences, Inc. (GILD) is expanding its influence in virology by acquiring promising startups in the fields of immunology and oncology. The scaling of drug production is supported by flexible collaboration with external contract manufacturers. This chart reflects total assets at 54950.21, while business resilience is based on dominance in HIV therapy and the introduction of innovative cancer drugs.

GILD (Gilead Sciences, Inc.) Company Total Assets history from 07/04/2022 to 11/01/2026

Analytical breakdowns and data insights for company Gilead Sciences Inc (GILD)

- stock quotes and analyst forecast:
Share Price gilead.com|GILD - Price Target Chart
- market capitalization data:
Market Valuation Gilead Corp|GILD - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share Gilead Sciences|GILD - Book Capitalization|Market Capitalization to Book Value Ratio gilead.com|GILD - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Gilead Sciences, Inc.|GILD - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Gilead Corp|GILD - Company Aggregate Debts|Debts to Book Capitalization Gilead Corp|GILD - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Gilead Sciences|Quick Liquidity gilead.com
- net income and valuation multiples indicators:
GILD - Net Profit
Fundamental valuation:Gilead Sciences, Inc.
Manufactured products of Gilead Sciences, Inc.

Gilead Sciences, Inc. (GILD) shifting its focus toward oncology and CAR-T therapy requires a significant expansion of its resource base. This metric, reverse-calculated via ROA, aggregates all controlled assets to benchmark business efficiency against competitors. By analyzing the total assets calculation, an investor can identify imbalances between asset growth and actual cash flows. The stable trend of this indicator confirms the successful diversification of the development portfolio.

Key competitors

Total Business Assets CDTX|Aggregate Company Assets Novavax|CureVac NV - Total Asset Value of Company|Company Total Assets VALN|VIR (Vir Corp) - Aggregate Asset Value|Company Total Assets SIGA (SIGA Technologies, Inc.)|Company Total Assets emergentbiosolutions.com EBS|AVIR - Aggregate Company Assets|Aggregate Asset Value IVVD (Invivyd, Inc.)|Enanta (ENTA) - Aggregate Company Assets|Cumulative Company Assets Inovio Pharma|HLVX (HilleVax, Inc.) - Company Total Assets|Company Total Assets kalaristx.com|Cumulative Company Assets DYAI (Dyadic International)|NNVC (nanoviricides.com) - Aggregate Asset Value|Talphera Corp - Cumulative Company Assets|Cocrystal Pharma Corp - Aggregate Company Assets|Traws Therapeutics - Company Total Assets|Company Total Asset Base Dogwood Therapeutics, Inc. DWTX|Qualigen Therapeutics, Inc. (QLGN) - Aggregate Company Assets|AlloVir - Aggregate Asset Value|Cumulative Company Assets VBIV|Company Total Assets Virios|Aggregate Company Assets Vaxart, Inc. (VXRT)